Who makes TRISTRONTIUM ALUMINATE?

TRISTRONTIUM ALUMINATE is developed by DR SURINDER SACHDEVA.

What development phase is TRISTRONTIUM ALUMINATE in?

TRISTRONTIUM ALUMINATE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

TRISTRONTIUM ALUMINATE

DR SURINDER SACHDEVA · FDA-approved active Small molecule Quality 2/100

Tristrontium Aluminate, marketed by Dr. Surinder Sachdeva, holds a niche position in the pharmaceutical market with its unique mechanism of action and primary indication. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue protection. However, the lack of detailed clinical trial results and revenue data poses a primary risk, potentially limiting investor confidence and market adoption.

At a glance

Generic name	TRISTRONTIUM ALUMINATE
Sponsor	DR SURINDER SACHDEVA
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Direct Pulp Capping Agent on Human Pulp Tissue (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TRISTRONTIUM ALUMINATE CI brief — competitive landscape report
TRISTRONTIUM ALUMINATE updates RSS · CI watch RSS
DR SURINDER SACHDEVA portfolio CI